Cargando…

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis

Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical causes of mortality worldwide. Intervention of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Zhou, Junteng, Wei, Zisong, Cheng, Yue, Tian, Geer, Quan, Yue, Kong, Qihang, Wu, Wenchao, Liu, Xiaojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393479/
https://www.ncbi.nlm.nih.gov/pubmed/36003513
http://dx.doi.org/10.3389/fphar.2022.940768
_version_ 1784771277548945408
author Chen, Yan
Zhou, Junteng
Wei, Zisong
Cheng, Yue
Tian, Geer
Quan, Yue
Kong, Qihang
Wu, Wenchao
Liu, Xiaojing
author_facet Chen, Yan
Zhou, Junteng
Wei, Zisong
Cheng, Yue
Tian, Geer
Quan, Yue
Kong, Qihang
Wu, Wenchao
Liu, Xiaojing
author_sort Chen, Yan
collection PubMed
description Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical causes of mortality worldwide. Intervention of pathological cardiac hypertrophy can effectively reduce the occurrence of heart failure. Abundant factors, such as adrenergic, angiotensin, and endothelin (ET-1) receptors, have been shown to participate in the regulation of pathological cardiac hypertrophy. Recently, an increasing number of studies have indicated that circRNA and circRNA-miRNA–mRNA network regulation is indispensable for the posttranscriptional regulation of mRNA in cardiac hypertrophy. In our study, the morphological, cardiac function and pathological changes during cardiac hypertrophy were investigated. RNA sequencing identified 93 circRNAs that were differentially expressed in the TAC_2w group, and 55 circRNAs in the TAC_4w group compared with the sham group. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses identified several significant pathways, including hypertrophic cardiomyopathy, extracellular matrix (ECM)-receptor interaction and focal adhesion. Coexpression analyses were performed for differentially expressed circRNAs and differentially expressed mRNAs. Based on gene set enrichment analysis (GSEA), 8 circRNAs (mmu-Nfkb1_0001, mmu-Smad4_0007, mmu-Hecw2_0009, mmu-Itgbl1_0002, mmu-Lrrc2_0005, mmu-Cpeb3_0007, mmu-Ryr2_0040, and mmu-Rtn4_0001) involved in cardiac hypertrophy and cardiac fibrosis were identified. We validated some key circRNAs by qPCR. The crucial coexpression of circRNA–mRNA and its interaction with miRNA showed the possible mechanism of circRNAs in the process of cardiac dysfunction. Our results may provide promising targets for the treatment of pathological cardiac hypertrophy and fibrosis.
format Online
Article
Text
id pubmed-9393479
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93934792022-08-23 Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis Chen, Yan Zhou, Junteng Wei, Zisong Cheng, Yue Tian, Geer Quan, Yue Kong, Qihang Wu, Wenchao Liu, Xiaojing Front Pharmacol Pharmacology Cardiac hypertrophy initially serves as an adaptive response to physiological and pathological stimuli. Sustained hypertrophy progress to pathological cardiac hypertrophy, cardiac fibrosis and ultimately lead to heart failure, one of the leading medical causes of mortality worldwide. Intervention of pathological cardiac hypertrophy can effectively reduce the occurrence of heart failure. Abundant factors, such as adrenergic, angiotensin, and endothelin (ET-1) receptors, have been shown to participate in the regulation of pathological cardiac hypertrophy. Recently, an increasing number of studies have indicated that circRNA and circRNA-miRNA–mRNA network regulation is indispensable for the posttranscriptional regulation of mRNA in cardiac hypertrophy. In our study, the morphological, cardiac function and pathological changes during cardiac hypertrophy were investigated. RNA sequencing identified 93 circRNAs that were differentially expressed in the TAC_2w group, and 55 circRNAs in the TAC_4w group compared with the sham group. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses identified several significant pathways, including hypertrophic cardiomyopathy, extracellular matrix (ECM)-receptor interaction and focal adhesion. Coexpression analyses were performed for differentially expressed circRNAs and differentially expressed mRNAs. Based on gene set enrichment analysis (GSEA), 8 circRNAs (mmu-Nfkb1_0001, mmu-Smad4_0007, mmu-Hecw2_0009, mmu-Itgbl1_0002, mmu-Lrrc2_0005, mmu-Cpeb3_0007, mmu-Ryr2_0040, and mmu-Rtn4_0001) involved in cardiac hypertrophy and cardiac fibrosis were identified. We validated some key circRNAs by qPCR. The crucial coexpression of circRNA–mRNA and its interaction with miRNA showed the possible mechanism of circRNAs in the process of cardiac dysfunction. Our results may provide promising targets for the treatment of pathological cardiac hypertrophy and fibrosis. Frontiers Media S.A. 2022-08-08 /pmc/articles/PMC9393479/ /pubmed/36003513 http://dx.doi.org/10.3389/fphar.2022.940768 Text en Copyright © 2022 Chen, Zhou, Wei, Cheng, Tian, Quan, Kong, Wu and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Yan
Zhou, Junteng
Wei, Zisong
Cheng, Yue
Tian, Geer
Quan, Yue
Kong, Qihang
Wu, Wenchao
Liu, Xiaojing
Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
title Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
title_full Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
title_fullStr Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
title_full_unstemmed Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
title_short Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
title_sort identification of circular rnas in cardiac hypertrophy and cardiac fibrosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393479/
https://www.ncbi.nlm.nih.gov/pubmed/36003513
http://dx.doi.org/10.3389/fphar.2022.940768
work_keys_str_mv AT chenyan identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT zhoujunteng identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT weizisong identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT chengyue identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT tiangeer identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT quanyue identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT kongqihang identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT wuwenchao identificationofcircularrnasincardiachypertrophyandcardiacfibrosis
AT liuxiaojing identificationofcircularrnasincardiachypertrophyandcardiacfibrosis